Surface plasmon resonance analysis of complex formation of therapeutic recombinant lysosomal enzymes with domain 9 of human cation-independent mannose 6-phosphate receptor-Reference-Cited by-同舟云学术

Surface plasmon resonance analysis of complex formation of therapeutic recombinant lysosomal enzymes with domain 9 of human cation-independent mannose 6-phosphate receptor

Published:2020-12 Issue: Volume:25 Page:100639
ISSN:2214-4269
Container-title:Molecular Genetics and Metabolism Reports
language:en
Short-container-title:Molecular Genetics and Metabolism Reports

Author:

Kanzaki Minori,Tsukimura Takahiro,Chiba Yasunori,Sakuraba Hitoshi,Togawa Tadayasu

Funder

Sumitomo Dainippon Pharma Co., Ltd

Sanofi Japan Co

JSPS KAKENHI

Publisher

Elsevier BV

Subject

Endocrinology,Genetics,Molecular Biology

Reference23 articles.

1. Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives;Solomon;Adv. Drug Deliv. Rev.,2017

2. Lysosomal diseases: Overview on current diagnosis and treatment;Poswer;Genet. Mol. Biol.,2019

3. I-cell disease and pseudo-hurler polydystrophy: Disorders of lysosomal enzyme phosphorylation and localization;Kornefeld,2001

4. Mannose 6-phosphate receptor targeting and its applications in human diseases;Gary-Bobo;Curr. Med. Chem.,2007

5. Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease;Prabakaran;PLoS One,2011

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative study on incorporation of three recombinant human α-galactosidase A drugs (agalsidases) into cultured fibroblasts and organs/tissues of Fabry mice;Molecular Genetics and Metabolism Reports;2024-09

2. Transferrin receptor-targeting property of pabinafusp alfa facilitates its uptake by various types of human brain-derived cells in vitro;Frontiers in Drug Delivery;2023-07-03

3. Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins;Advanced Drug Delivery Reviews;2022-05

4. Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid;Metabolic Brain Disease;2022-01-28

5. Collateral damage of the COVID-19 pandemic on lysosomal storage diseases: A single unit experience;Annals of Clinical and Analytical Medicine;2022